Explore 3 Stock Ideas & Industry Insights Download Free Report

Park Ha Biological Technology Co., Ltd.

Company price
2.1594 USD 0.07 ( 3.32%)
Last update at 2026-11-06T21:00:00Z
VOLUME
4284
Market Cap
3.49M

Momentum Score

…

Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. It operates in two segments, Product Sales and Franchise Service. The company offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells products to customers through directly operated retail stores, and franchisees. The company was founded in 2016 and is headquartered in Wuxi, the People's Republic of China. Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.10
Low
2.30
High
52 Week Price Range
0.93
Low
2074.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) identifies as a China-based biological technology company but provides limited public disclosures. Long-term growth drivers could include rising domestic healthcare demand and broader biotech adoption, but company-specific products and strategy are unclear; investors seeking small-cap China biotech exposure may view it as speculative.

Key risks include limited transparency, low trading liquidity, governance and regulatory uncertainty for China-listed U.S. stocks, and execution risk for a small, early-stage business.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.09
Dividend Yield
-
Revenue TTM
2.52M
Revenue Per Share
4.29
Gross Profit TTM
2.38M
Debt / Equity
0.05
ROE
-885.84%
Net Debt
-3.61M
ROCE
-593.23%
Diluted EPS TTM
-2069.00

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Income before tax -24.08M 0.79M 1.18M 0.19M -0.48M
Net income -24.36M 0.48M 0.85M 0.19M -0.48M
Selling general administrative 26.11M 0.81M 0.48M 0.71M 0.75M
Selling and marketing expenses - 0.36M 0.30M 0.44M 0.37M
Gross profit 2.38M 2.19M 2.15M 1.41M 0.62M
Reconciled depreciation 0.11M 0.02M 0.02M 0.03M 0.04M
Ebit -24.15M 0.79M 1.18M 0.19M -0.48M
Ebitda -24.04M 0.82M 1.20M 0.22M -0.44M
Depreciation and amortization 0.11M 0.02M 0.02M 0.03M 0.04M
Operating income -24.15M 0.79M 1.18M 0.20M -0.50M
Other operating expenses 26.67M 1.59M 1.28M 1.72M 1.43M
Interest expense 0.00M 0.00M 0.00M 0.00M 0.00M
Tax provision 0.28M 0.31M 0.33M -0.00M 0.00M
Interest income 0.01M 0.00M 0.00M 0.00M 0.00M
Net interest income 0.01M 0.00M 0.00M 0.00M -0.00M
Income tax expense 0.28M 0.31M 0.33M -0.00M -
Total revenue 2.52M 2.38M 2.46M 1.92M 0.93M
Total operating expenses 26.53M 1.39M 0.97M 1.21M 1.12M
Cost of revenue 0.14M 0.20M 0.31M 0.51M 0.31M
Total other income expense net 0.06M -0.00M 0.00M -0.01M 0.02M
Net income from continuing ops -24.36M 0.48M 0.85M 0.19M -0.48M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Total assets 5.95M 3.08M 2.26M 2.52M 0.59M
Intangible assets 0.01M 0.01M 0.01M 0.01M -
Other current assets 0.33M 1.12M 0.34M 0.07M 0.00M
Total liab 1.96M 1.58M 1.25M 2.37M 1.17M
Total stockholder equity 3.99M 1.51M 1.01M 0.15M -0.58M
Other current liab 1.57M 0.16M 0.19M 0.85M 0.79M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -24.18M 0.27M -0.11M -0.93M -1.12M
Cash 3.79M 0.55M 1.03M 0.57M 0.07M
Total current liabilities 1.88M 1.52M 1.24M 2.37M 1.16M
Current deferred revenue 0.19M 0.33M 0.25M 1.21M 0.16M
Net debt -3.61M -0.48M -1.00M -0.55M -0.04M
Short term debt 0.10M 0.02M 0.02M 0.03M 0.02M
Short long term debt total 0.18M 0.07M 0.03M 0.03M 0.04M
Other stockholder equity 28.02M 1.16M 1.16M 1.12M 0.59M
Total current assets 5.50M 2.84M 2.18M 2.26M 0.47M
Net receivables 1.30M 1.11M 0.71M 1.53M 0.08M
Inventory 0.08M 0.07M 0.10M 0.09M 0.32M
Accounts payable 0.01M 0.02M 0.20M 0.13M 0.09M
Accumulated other comprehensive income 0.15M 0.07M -0.04M -0.05M -0.05M
Non currrent assets other 0.02M 0.00M 0.01M 0.18M 0.01M
Non current assets total 0.45M 0.24M 0.09M 0.25M 0.12M
Capital lease obligations 0.18M 0.07M 0.03M 0.03M 0.04M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Investments - -0.51M 1.02M -1.55M -0.01M
Total cashflows from investing activities -0.57M -0.51M 1.02M -1.55M -0.01M
Net borrowings 0.01M -0.07M -0.72M 0.14M 0.24M
Total cash from financing activities 3.74M -0.96M -0.68M 0.67M 0.50M
Net income -24.36M 0.48M 0.85M 0.19M -0.48M
Change in cash 3.24M -0.49M 0.46M 0.50M -0.01M
Begin period cash flow 0.55M 1.03M 0.57M 0.07M 0.08M
End period cash flow 3.79M 0.55M 1.03M 0.57M 0.07M
Total cash from operating activities 0.09M 0.96M 0.13M 1.44M -0.50M
Issuance of capital stock 4.28M 0.00M 0.04M 0.53M 0.26M
Depreciation 0.11M 0.02M 0.02M 0.03M 0.04M
Other cashflows from investing activities -0.48M -0.42M 1.05M -1.54M -
Change to inventory -0.01M 0.01M -0.00M 0.19M -0.02M
Change to account receivables -0.25M -0.14M -0.60M -0.14M -0.05M
Other cashflows from financing activities 0.01M -0.89M - - -
Capital expenditures 0.09M 0.09M 0.02M 0.01M 0.01M
Change in working capital -0.09M 0.25M -0.91M 1.17M -0.05M
Stock based compensation 24.07M 0.00M 0.00M - -
Other non cash items 24.46M 0.23M 0.20M 0.05M 0.00M
Free cash flow -0.00M 0.87M 0.10M 1.43M -0.51M

Peer Comparison*

Sector: Consumer Defensive Industry: Household & Personal Products

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BYAH
Park Ha Biological Technology Co., Ltd.
0.07
3.32%
2.16 - - 1.38 0.89 0.03 15.52
PG
Procter & Gamble Company
-1.70
1.02%
165.40 23.58 22.62 4.07 7.24 4.40 16.08
LRLCF
L'Oréal S.A
-25.50
5.05%
479.50 41.14 34.25 6.52 8.59 6.67 27.76
LRLCY
L’Oreal Co ADR
-1.19
1.17%
100.37 32.44 25.64 5.16 6.03 4.79 19.51
UL
Unilever PLC ADR
-1.71
2.53%
66.00 21.53 16.39 2.66 7.29 2.77 12.45

Profile*

Park Ha Biological Technology Co., Ltd.

Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. It operates in two segments, Product Sales and Franchise Service. The company offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells products to customers through directly operated retail stores, and franchisees. The company was founded in 2016 and is headquartered in Wuxi, the People's Republic of China. Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd.

Building C, Wuxi, China, 214100

86 40 0012 7562

41

Name Title Year Born
Ms. Xiaoqiu Zhang CEO & Chairman of the Board 1981
Ms. Xiaoyan Zhu Chief Financial Officer 1978
Ms. Xinyu Li CTO & Product Manager 1986

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…